Invesco’s vTv Therapeutics VTVT Stock Holding History

Invesco’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-752	Closed	-$85K	–	4039
2021 Q1	$85K	Buy	752 +10	+1%	+$982	﹤0.01%	3777
2020 Q4	$55K	Buy	+742	New	+$56.9K	﹤0.01%	3736

Other funds holding VTVT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WAG

Winthrop Advisory Group Boston, Massachusetts $1.48B AUM 22.62% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CIM

CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Invesco's VTVT Position: Q2 2021 in Review

Invesco sold out of vTv Therapeutics (VTVT) in Q2 2021, closing a stake of 752 shares — an estimated $85K sold.

Invesco first reported a position in VTVT in Q4 2020 and held it in 2 quarters. The position peaked at $85K in Q1 2021. 42 funds tracked by Wall St. Rank hold VTVT as of Q2 2021.

Invesco reported no remaining vTv Therapeutics position as of Q2 2021 after selling out during the quarter.
Invesco sold 752 vTv Therapeutics shares in Q2 2021, an estimated $85K.
Invesco first reported a position in vTv Therapeutics in Q4 2020 and held it in 2 quarters.
Invesco's vTv Therapeutics position peaked at $85K in Q1 2021.
42 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2021.

Based on Invesco's 13F filing for Q2 2021, filed 17 Aug 2021.